Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study concluded that intraprostatic injection with drugs and high frequency thermotherapy was more effective for treating prostatitis after TURP than a combination of antibiotherapy, tamsulosin, and finasteride.

This study observed that Poria cocos polysaccharides and finasteride both reduced inflammation in chronic nonbacterial prostatitis in rats, but only Poria cocos polysaccharides reversed related changes in the gut microbiota.

In this study, dual therapy with tamsulosin and solifenacin significantly improved urinary symptom severity and bladder capacity in BPH patients, but did not alter post-void residual urine volume. This supports using the combination therapy for managing LUTS, especially for storage-related symptoms, in clinical settings.

The researchers reported that cancer incidences are rising over time in developed countries, with potential carcinogenic drivers including advancing age, estrogen, decreasing vitamin D3, and Human Papillomavirus.

Larger prostate size in older men may be linked to poorer semen quality and fertility issues.

Long-term diabetes is linked to lower prostate cancer risk.

This study found that men with early-onset androgenetic alopecia had significantly larger prostate volumes and lower urinary flow rates compared to healthy controls, suggesting a possible link between AGA and prostate-related urinary symptoms.

This study found that long-term finasteride therapy in men with BPH worsened erectile dysfunction and reduced testosterone levels, while these effects were not observed with tamsulosin.

This article discusses androgenetic alopecia as a potential early marker for benign prostatic hyperplasia but reports no new clinical findings.

This study found that while new treatments like Optilume, Rezum, and Aquablation have minimal risks of sexual dysfunction, they offer less improvement in lower urinary tract symptoms compared to traditional surgeries like TURP, though Aquablation does reduce ejaculatory dysfunction more effectively than TURP.

This study concluded that cyproterone acetate alone produced antiandrogenic effects on the female gerbil prostate, while ethinyloestradiol alone stimulated estrogenic activity, and their combination led to prostatic lesions.

In this study on testosterone-induced benign prostatic hyperplasia in rats, hydroxychloroquine significantly reduced prostate-related markers and enhanced therapeutic effects when combined with finasteride, suggesting potential as a new treatment approach.

This study found that Thermobalancing therapy using Dr Allen's Device significantly improved symptoms and quality of life in men with benign prostatic hyperplasia, but larger prostate sizes may require longer treatment.

This study aimed to estimate the value of urine prostate specific antigen (uPSA) as a marker for benign prostatic hyperplasia (BPH) but reported no new clinical findings.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This case report from the authors highlights a rare diagnosis of high-grade prostate cancer in a 35-year-old man, showing strong functional recovery and no detectable PSA one year after robotic-assisted radical prostatectomy despite the usual onset being significantly later in life.

This study observed that men with frontal and moderate vertex baldness between ages 40 and 50 had a higher risk of aggressive prostate cancer, suggesting a potential link between baldness pattern and cancer risk.

This study found that among prostate cancer patients undergoing a biopsy, those with metabolic syndrome tended to have a lower Gleason score compared to those without the syndrome.

This review discusses current and emerging treatments for benign prostatic hyperplasia and emphasizes the need for further research to optimize treatment selection, but reports no new clinical results.

This review describes the roles of 5α-reductase isozymes in prostate development and pathology and reports no new clinical results.

This study found that 1-year use of 5alpha-reductase inhibitors, dutasteride or finasteride, significantly lowered dihydrotestosterone levels without adversely affecting bone density, lipids, or hemoglobin in normal men.

This study observed that finasteride use among men with benign prostatic hyperplasia was associated with a decreased incidence of low-grade prostate cancer but not high-grade tumors.

In this study, treatment with 1 mg of finasteride was associated with stable sexual function, suggesting that sexual side effects may be less common than indicated in clinical trials.

This review provides a comprehensive overview of the mechanisms, efficacy, and adverse reactions of drugs commonly used for treating benign prostatic hyperplasia but reports no new clinical results.

This study found that men aged 50 and older with clinical benign prostatic hyperplasia have a significantly higher prevalence of metabolic syndrome than those without the condition in the UK primary care population.

This study found that Ganoderma lucidum extracts reduced prostate enlargement and improved symptoms in testosterone-treated rats, suggesting potential benefits for managing benign prostatic hyperplasia.

Benign Prostatic Hyperplasia may be caused by changes in how the body processes male hormones.

This review analyzes the potential mechanisms by which SARS-CoV-2 may exacerbate symptoms of benign prostatic hyperplasia and suggests a connection via ACE2 and androgen receptor pathways; it reports no new clinical results.

This study found that early-onset baldness in African-American men is associated with an increased risk of developing prostate cancer and more aggressive tumors, with potential interactions involving age and smoking.

This study suggests that any baldness, particularly moderate balding, is associated with a higher risk of fatal prostate cancer in men, supporting a possible link between hair loss and prostate cancer mechanisms.